FOLFIRI after liver surgery for colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding FOLFIRI chemotherapy after surgery for liver metastases from colorectal cancer can reduce the risk of the cancer coming back. It's for people whose liver tumors responded well to the same chemotherapy before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had surgery to remove all cancer from your liver, and the cancer started in the colon or rectum.
- Your liver cancer came back more than 12 months after treating the original colon or rectal cancer.
- You received 2 to 8 cycles of FOLFIRI chemotherapy (with or without targeted therapy) before the liver surgery.
- Your liver tumors shrank or disappeared after the pre-surgery chemotherapy (shown on scans or from the tissue removed).
- You have no cancer outside the liver on a CT scan done within 6 weeks after surgery.
- You are 18 or older, in good general health, and have no bowel disease or enzyme problems that would make the chemotherapy unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial checks whether giving chemotherapy after surgery only for people whose blood test (ctDNA) shows no remaining cancer can help prevent the cancer from coming back. It is for people with colon cancer that has spread to the liver who had the tumor fully removed.
This trial tests a combination of three chemotherapy drugs (liposomal irinotecan, oxaliplatin, and capecitabine) given directly into the liver blood vessel after surgery to remove colorectal cancer that has spread to the liver. The goal is to reduce the chance of cancer coming back.
This trial tests whether adding two targeted drugs (serplulimab and bevacizumab) to standard chemotherapy before surgery can improve outcomes for people with colorectal cancer that has spread to the liver. It is for those whose cancer has certain genetic features and is considered resectable.
This Phase 3 trial tests whether an added “maintenance” treatment after liver surgery can help prevent colorectal cancer from coming back. It is only for people whose blood test (ctDNA) still shows signs of cancer after their operation.
This Phase 3 trial tests a treatment approach for colorectal cancer that cannot be removed with surgery at first but has spread only to the liver. It is intended for people whose tumor is RAS/BRAF “wild-type” and who are well enough to do daily activities, to see if the treatment can control the cancer better.
This trial studies whether giving chemotherapy after surgery or ablation (destroying spots of cancer) can improve outcomes in people with metastatic colon or rectal cancer. It compares post-treatment chemotherapy strategies to reduce the chance the cancer comes back.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.